新华制药(000756.SZ)：子公司获得非那雄胺片药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Group 1: Product Information - Finasteride tablets are used to treat and control benign prostatic hyperplasia (BPH) and to prevent urinary system events [1] - The medication reduces the risk of acute urinary retention and the need for transurethral resection of the prostate (TURP) and prostatectomy [1] - Finasteride tablets can shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]